XOMA Corp (NASDAQ:XOMA) insider Value Fund L. P. Biotechnology bought 25,000 shares of the firm’s stock in a transaction that occurred on Monday, December 17th. The shares were acquired at an average price of $14.19 per share, with a total value of $354,750.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Shares of NASDAQ:XOMA traded down $0.40 during trading on Friday, reaching $14.00. The company had a trading volume of 60,802 shares, compared to its average volume of 73,260. The firm has a market cap of $122.46 million, a P/E ratio of 14.29 and a beta of 2.51. The company has a current ratio of 5.38, a quick ratio of 5.38 and a debt-to-equity ratio of 19.16. XOMA Corp has a fifty-two week low of $11.02 and a fifty-two week high of $34.72.
XOMA (NASDAQ:XOMA) last released its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.40). The company had revenue of $0.90 million during the quarter, compared to analyst estimates of $0.83 million. XOMA had a negative net margin of 129.85% and a negative return on equity of 267.64%. Research analysts forecast that XOMA Corp will post -1.73 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in XOMA by 0.8% during the third quarter. BlackRock Inc. now owns 452,542 shares of the biotechnology company’s stock worth $7,951,000 after acquiring an additional 3,686 shares during the period. Vanguard Group Inc grew its holdings in XOMA by 1.0% during the third quarter. Vanguard Group Inc now owns 311,093 shares of the biotechnology company’s stock worth $5,466,000 after acquiring an additional 3,167 shares during the period. Vanguard Group Inc. grew its holdings in XOMA by 1.0% during the third quarter. Vanguard Group Inc. now owns 311,093 shares of the biotechnology company’s stock worth $5,466,000 after acquiring an additional 3,167 shares during the period. Acadian Asset Management LLC grew its holdings in XOMA by 6.0% during the third quarter. Acadian Asset Management LLC now owns 101,820 shares of the biotechnology company’s stock worth $1,789,000 after acquiring an additional 5,769 shares during the period. Finally, Northern Trust Corp grew its holdings in XOMA by 308.6% during the second quarter. Northern Trust Corp now owns 68,200 shares of the biotechnology company’s stock worth $1,424,000 after acquiring an additional 51,510 shares during the period. 42.86% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have weighed in on XOMA shares. HC Wainwright reiterated a “buy” rating and issued a $49.00 price objective on shares of XOMA in a research note on Friday, September 21st. Cowen reiterated a “hold” rating on shares of XOMA in a research note on Thursday, November 8th. ValuEngine upgraded XOMA from a “sell” rating to a “hold” rating in a research note on Tuesday, December 11th. Wedbush reiterated an “outperform” rating on shares of XOMA in a research note on Monday, September 17th. Finally, TheStreet cut XOMA from a “c-” rating to a “d-” rating in a research note on Monday, November 26th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. XOMA currently has an average rating of “Hold” and a consensus target price of $28.07.
WARNING: “XOMA Corp (XOMA) Insider Buys $354,750.00 in Stock” was first reported by PressOracle and is the property of of PressOracle. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://pressoracle.com/news/2019/01/12/value-fund-l-p-biotechnology-purchases-25000-shares-of-xoma-corp-xoma-stock.html.
XOMA Company Profile
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.
Recommended Story: What are different types of coverage ratios?
Receive News & Ratings for XOMA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for XOMA and related companies with MarketBeat.com’s FREE daily email newsletter.